Free Trial

CEL-SCI (CVM) Competitors

CEL-SCI logo
$2.49 -0.03 (-1.19%)
Closing price 07/3/2025 03:30 PM Eastern
Extended Trading
$2.48 -0.01 (-0.24%)
As of 07/3/2025 05:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CVM vs. GRCE, MRNS, MAAQ, ALLK, SXTC, INKT, RANI, SCYX, DYAI, and FBLG

Should you be buying CEL-SCI stock or one of its competitors? The main competitors of CEL-SCI include Grace Therapeutics (GRCE), Marinus Pharmaceuticals (MRNS), Mana Capital Acquisition (MAAQ), Allakos (ALLK), China SXT Pharmaceuticals (SXTC), MiNK Therapeutics (INKT), Rani Therapeutics (RANI), SCYNEXIS (SCYX), Dyadic International (DYAI), and FibroBiologics (FBLG). These companies are all part of the "pharmaceutical products" industry.

CEL-SCI vs. Its Competitors

CEL-SCI (NYSE:CVM) and Grace Therapeutics (NASDAQ:GRCE) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability.

Grace Therapeutics is trading at a lower price-to-earnings ratio than CEL-SCI, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CEL-SCIN/AN/A-$26.92M-$12.61-0.20
Grace TherapeuticsN/AN/A-$9.57M-$0.89-3.52

In the previous week, CEL-SCI's average media sentiment score of 0.00 equaled Grace Therapeutics'average media sentiment score.

Company Overall Sentiment
CEL-SCI Neutral
Grace Therapeutics Neutral

Grace Therapeutics has a consensus target price of $12.00, suggesting a potential upside of 283.39%. Given Grace Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Grace Therapeutics is more favorable than CEL-SCI.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CEL-SCI
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Grace Therapeutics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

12.1% of CEL-SCI shares are held by institutional investors. Comparatively, 6.1% of Grace Therapeutics shares are held by institutional investors. 9.9% of CEL-SCI shares are held by company insiders. Comparatively, 13.5% of Grace Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Grace Therapeutics' return on equity of -19.45% beat CEL-SCI's return on equity.

Company Net Margins Return on Equity Return on Assets
CEL-SCIN/A -238.05% -104.65%
Grace Therapeutics N/A -19.45%-16.99%

CEL-SCI has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500. Comparatively, Grace Therapeutics has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500.

Summary

Grace Therapeutics beats CEL-SCI on 10 of the 11 factors compared between the two stocks.

Get CEL-SCI News Delivered to You Automatically

Sign up to receive the latest news and ratings for CVM and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CVM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CVM vs. The Competition

MetricCEL-SCIBiological Products IndustryMedical SectorNYSE Exchange
Market Cap$7.55M$205.22M$5.56B$20.71B
Dividend YieldN/AN/A5.22%3.71%
P/E Ratio-5.19N/A27.6628.10
Price / SalesN/A223.65423.0038.31
Price / CashN/A22.4436.8922.53
Price / Book16.605.618.034.58
Net Income-$26.92M-$96.61M$3.18B$985.54M
7 Day Performance3.75%-0.57%2.93%2.79%
1 Month Performance4.62%-3.74%1.72%4.37%
1 Year Performance-93.14%10.50%34.39%15.08%

CEL-SCI Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CVM
CEL-SCI
0.0706 of 5 stars
$2.49
-1.2%
N/A-93.1%$7.55MN/A-5.1943High Trading Volume
GRCE
Grace Therapeutics
1.7644 of 5 stars
$2.93
-2.3%
$12.00
+309.6%
N/A$30.42MN/A-2.53N/AGap Down
High Trading Volume
MRNS
Marinus Pharmaceuticals
2.3379 of 5 stars
$0.55
-0.2%
$3.92
+613.3%
-54.2%$30.32M$30.99M-0.22110News Coverage
MAAQ
Mana Capital Acquisition
N/A$3.71
-4.6%
N/A+603.6%$30.14MN/A0.001
ALLK
Allakos
2.8748 of 5 stars
$0.33
flat
$2.00
+507.7%
N/A$29.74MN/A-0.16190
SXTC
China SXT Pharmaceuticals
0.1382 of 5 stars
$1.84
flat
N/A-78.1%$29.12M$1.93M0.0090News Coverage
INKT
MiNK Therapeutics
3.2702 of 5 stars
$7.48
+3.0%
$37.50
+401.3%
-25.3%$28.94MN/A-2.9730
RANI
Rani Therapeutics
1.5126 of 5 stars
$0.49
-2.1%
$7.33
+1,396.6%
-85.6%$28.77M$1.03M-0.49110
SCYX
SCYNEXIS
0.2634 of 5 stars
$0.73
-0.6%
N/A-60.9%$28.65M$3.75M-1.3060
DYAI
Dyadic International
2.004 of 5 stars
$0.94
+2.9%
$6.00
+539.7%
-35.3%$27.44M$3.49M-4.697News Coverage
Gap Up
FBLG
FibroBiologics
2.2982 of 5 stars
$0.72
+3.6%
$13.00
+1,703.3%
-87.0%$26.61MN/A-3.4310Gap Up

Related Companies and Tools


This page (NYSE:CVM) was last updated on 7/6/2025 by MarketBeat.com Staff
From Our Partners